Barnes & Thornburg Advises BlossomHill Therapeutics In $100M Series B Financing Round
February 29, 2024
February 29, 2024
INDIANAPOLIS, Indiana, Feb. 29 -- Barnes and Thornburg, a law firm, issued the following news release:
Barnes & Thornburg's corporate and intellectual property attorneys advised BlossomHill Therapeutics, Inc., a biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, on its $100 million Series B financing round.
The financing, which brings the total capital raised by the company to $173 mil . . .
Barnes & Thornburg's corporate and intellectual property attorneys advised BlossomHill Therapeutics, Inc., a biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, on its $100 million Series B financing round.
The financing, which brings the total capital raised by the company to $173 mil . . .